We are live on ! Find out more

2,879 hedge funds and large institutions have $105B invested in Pfizer in 2024 Q2 according to their latest regulatory filings, with 211 funds opening new positions, 1,186 increasing their positions, 1,242 reducing their positions, and 173 closing their positions.

New
Increased
Maintained
Reduced
Closed

22% more first-time investments, than exits

New positions opened: 211 | Existing positions closed: 173

6% more funds holding in top 10

Funds holding in top 10: 3133 (+2)

0% less funds holding

Funds holding: 2,8822,879 (-3)

1% less capital invested

Capital invested by funds: $106B → $105B (-$763M)

5% less repeat investments, than reductions

Existing positions increased: 1,186 | Existing positions reduced: 1,242

1.27% less ownership

Funds ownership: 67.35%66.08% (-1.3%)

40% less call options, than puts

Call options by funds: $2.36B | Put options by funds: $3.9B

Holders
2,879
Holders Change
-3
Holders Change %
-0.1%
% of All Funds
41.51%
Holding in Top 10
33
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+6.45%
% of All Funds
0.48%
New
211
Increased
1,186
Reduced
1,242
Closed
173
Calls
$2.36B
Puts
$3.9B
Net Calls
-$1.54B
Net Calls Change
+$77.4M

PFE Hedge Fund Activity: Q2 2024 in Review

2,879 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q2 2024, worth a combined $105B — down 0.72% from $106B a quarter earlier.

Buyers outnumbered sellers: 211 funds opened new PFE positions and 173 closed out — a net gain of 38 holders — while 1,186 added to existing stakes and 1,242 trimmed.

The largest buyer was Goldman Sachs, adding an estimated $346M. The largest seller was Capital World Investors, cutting an estimated $675M.

  • 2,879 institutional investors held Pfizer (PFE) as of Q2 2024, down from 2,882 in Q1 2024.
  • Funds reported $105B of Pfizer stock for Q2 2024, down 0.72% quarter-over-quarter.
  • 211 funds opened new Pfizer positions in Q2 2024 and 173 closed out, a net change of +38 holders.
  • The largest Pfizer buyer in Q2 2024 was Goldman Sachs, an estimated $346M added.
  • The largest Pfizer seller in Q2 2024 was Capital World Investors, an estimated $675M sold.

Based on aggregated 13F filings for Q2 2024.